López Santamaría M, Hernández Oliveros F
Hospital Universitario La Paz, Departamento de Cirugía Pediátrica, Madrid, España.
Nutr Hosp. 2007 May;22 Suppl 2:113-23.
The most recent outcomes on bowel transplantation (BT), with a survival rate immediately after transplant higher than 80% and a great rate of survivors achieving complete digestive autonomy and able to carry out activities according to their age allow for considering BT as the first choice therapy in patients with irreversible intestinal failure in whom poor prognosis with parenteral nutrition is foreseen. Parenteral nutrition-associated liver damage is the most frequent indication for BT, especially in children that are more susceptible than adults to develop this complication. Other accepted indications for BT are irreversible intestinal failure in association with loss of deep venous accesses, life-threatening severe infections associated with the use of central catheters, and those cases of intestinal failure usually leading to early death, such as ultra-short bowel syndromes, refractory diarrheas, and intestinal failure associated to high morbidity and poor quality of life. BT is performed in human clinical practice under three technical modalities: isolated bowel transplant, combined liver-bowel transplant, and multi-visceral transplantation. Currently, refinements of original techniques including reduction of liver and/or intestinal grafts, grafts from living donors, etc., allow for overcoming the different needs as well as increasing the likelihood of having access to transplantation, which is a desirable goal specially in very young or very low-weighted children candidate to liver-bowel transplant. One of the most interesting issues in BT programs is having given access to the Intestinal Rehabilitation Units, which comprise the three therapeutic modalities by means of a multidisciplinary team: nutritional support, pharmacotherapy, and surgery. These Units optimize the outcomes, minimize costs, and allow for offering a management adapted to individual needs.
肠道移植(BT)的最新成果显示,移植后即刻生存率高于80%,且很大比例的存活者实现了完全消化自主,能够根据自身年龄开展活动,这使得BT可被视为预计肠外营养预后不良的不可逆肠衰竭患者的首选治疗方法。肠外营养相关肝损伤是BT最常见的适应证,尤其是在儿童中,他们比成人更容易发生这种并发症。BT的其他公认适应证包括与深部静脉通路丧失相关的不可逆肠衰竭、与使用中心静脉导管相关的危及生命的严重感染,以及通常导致早期死亡的肠衰竭病例,如超短肠综合征、难治性腹泻,以及与高发病率和低生活质量相关的肠衰竭。BT在人类临床实践中有三种技术方式:孤立肠移植、肝肠联合移植和多脏器移植。目前,对原始技术的改进,包括减少肝脏和/或肠道移植物、使用活体供体的移植物等,能够满足不同需求,同时增加了获得移植的可能性,这对于肝肠移植候选的极低体重幼儿来说是一个理想的目标。BT项目中最有趣的问题之一是建立了肠道康复单元,该单元通过多学科团队涵盖了三种治疗方式:营养支持、药物治疗和手术。这些单元优化了治疗效果,降低了成本,并能提供适应个体需求的管理方案。